Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    BMC Res Notes. 2010 Mar 18;3:80. doi: 10.1186/1756-0500-3-80.

    Performance evaluation of commercial miRNA expression array platforms.

    Source

    Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe Street, Baltimore, MD 21205, USA. ririzarr@jhsph.edu.

    Abstract

    BACKGROUND:

    microRNAs (miRNA) are short, endogenous transcripts that negatively regulate the expression of specific mRNA targets. The relative abundance of miRNAs is linked to function in vivo and miRNA expression patterns are potentially useful signatures for the development of diagnostic, prognostic and therapeutic biomarkers.

    FINDING:

    We compared the performance characteristics of four commercial miRNA array technologies and found that all platforms performed well in separate measures of performance.

    CONCLUSIONS:

    The Ambion and Agilent platforms were more accurate, whereas the Illumina and Exiqon platforms were more specific. Furthermore, the data analysis approach had a large impact on the performance, predominantly by improving precision.

    PMID:
    20298588
    [PubMed]
    PMCID:
    PMC2853548
    Free PMC Article

    Images from this publication.See all images (2)Free text

    Figure 1
    Figure 2

      Supplemental Content

      Icon for BioMed Central Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk